About the Company
We do not have any company description for Neumora Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Neumora Therapeutics, Inc.
Mizuho Raises Price Target for Neumora (NMRA), Keeps Outperform Rating
Neumora Therapeutics, Inc. (NASDAQ:NMRA) is one of the 11 Best New Penny Stocks to Buy Right Now. On July 16, Mizuho increased its price target for Neumora Therapeutics, Inc. (NASDAQ:NMRA) from $4 to ...
Neumora Therapeutics, Inc. Sued for Securities Law Violations ...
Neumora Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights - NMRA PR Newswire NEW YORK, Feb. 20, 2025 ...
Neumora Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds ...
If you suffered a loss in Neumora Therapeutics, Inc. during the relevant time frame, you have until April 7, 2025 to request that the Court appoint you as lead plaintiff.
Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Initiated Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study with M4 positive allosteric modulator (PAM) NMRA-861, with data expected in the first quarter of 2026 Announces ...
NMRA INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces That ...
SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLPannounces that purchasers or acquirers of Neumora Therapeutics, Inc. (NASDAQ: NMRA) common stock pursuant and/or ...
Class Action Filed Against Neumora Therapeutics, Inc. (NMRA) Seeking ...
Class Action Filed Against Neumora Therapeutics, Inc. (NMRA) Seeking Recovery for Investors - Contact Levi & Korsinsky PRESS RELEASE ACCESS Newswire Feb. 28, 2025, 10:45 AM ...
NMRA INVESTOR ALERT: Neumora Therapeutics, Inc. Investors with ...
SAN DIEGO, Feb. 20, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Neumora Therapeutics, Inc. (NMRA) common stock pursuant and/or traceable to ...
Neumora Therapeutics, Inc. (NMRA) Q4 2024 Earnings Call Transcript
Neumora Therapeutics, Inc. (NASDAQ: NMRA) Q4 2024 Results Conference Call March 3, 2025 8:00 AM ET Company Participants Helen Rubinstein - Vice President of Investor Relations & Communications ...
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $10.14 Consensus ...
Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases.
Investor Alert: Robbins LLP Informs Investors of the Neumora ...
To be notified if a class action against Neumora Therapeutics, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc ...
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can ...
Neumora Therapeutics, Inc. Is Being Sued For Securities Law Violations ...
Neumora Therapeutics, Inc. Is Being Sued For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm PRESS RELEASE ACCESS Newswire Feb. 15, 2025, 11:00 AM ...
Similar Companies
Loading the latest forecasts...